Lin BioScience, Inc.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
TWO · 7754.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 06:44 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
AnnJi’s quoted price sits in the upper half of its reported 52-week range, 25.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Founded in 2014 and headquartered in Taipei, Taiwan, AnnJi Pharmaceutical Co., Ltd. specializes in the creation of innovative medicinal treatments. The company's research and development pipeline addresses neurological, dermatological, and inflammatory conditions. Among its key therapeutic candidates are AJ201, which is being developed for the neurodegenerative disorder spinal and bulbar muscular atrophy, and AJ202, targeting androgenetic alopecia. AnnJi also works on AJ302, a histone deacetylase 6 inhibitor aimed at preventing and treating chemotherapy-induced peripheral neuropathy, and AJ303, an anti-fibrotic and anti-inflammatory agent intended for idiopathic pulmonary fibrosis and other fibrotic diseases.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$68.40-NT$2.40 (-3.39%)
Lumosa Therapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
NT$58.20+NT$1.50 (+2.65%)
PharmaEngine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
NT$45.40-NT$3.10 (-6.39%)
OBI Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.04% below the high.
NT$17.90-NT$0.10 (-0.56%)
TWi Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.71% below the high.
NT$54.00-NT$1.70 (-3.05%)
Sinew Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.47% below the high.
NT$27.95-NT$0.45 (-1.58%)
BRIM Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.34% below the high.
NT$24.60-NT$0.20 (-0.81%)
Formosa Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.13% below the high.